Interstitial Lung Disease
Female patients with Sjögren’s syndrome more like to exhibit eye symptoms than males
There are several differences in the symptoms reported among male and female patients with primary Sjögren’s syndrome, according to data published in the Journal of Clinical Rheumatology.
Ziritaxestat fails to improve lung function in patients with idiopathic pulmonary fibrosis
WASHINGTON — In patients with idiopathic pulmonary fibrosis, yearly lung function decline rates did not improve with two different dosages of ziritaxestat, according to an American Thoracic Society International Conference presentation.
High levels of air pollution linked to ILD prevalence, acute exacerbations, death
WASHINGTON — Exposure to air pollutants at high levels contributed to interstitial lung disease incidence, acute exacerbations and death, according to an abstract presented at the American Thoracic Society International Conference.
Hunting for the ‘elusive’ Sjögren’s diagnosis: How multiple specialties can improve delays
In rheumatology, there is no shortage of conditions that are difficult to diagnose, with diseases like fibromyalgia and systemic lupus erythematosus sometimes taking years before being officially identified — leading to adverse outcomes.
Certain elevated biomarkers aid in diagnosis of systemic sclerosis-related ILD
For diagnosing systemic sclerosis-related ILD, Krebs von den Lungen-6, surfactant protein-D and interleukin-8 in blood/bronchoalveolar lavage fluid samples were found to be “reliable biomarkers,” according to results published in Thorax.
Composite serum biomarker may improve identification of interstitial lung disease in SSc
A composite biomarker index could improve the risk stratification and diagnosis of interstitial lung disease in patients with systemic sclerosis, according to data published in Arthritis & Rheumatology.
Patients with pulmonary arterial hypertension with CTD exhibit 59% 10-year survival rate
Patients with pulmonary arterial hypertension associated with connective tissue disease demonstrate a “poor” 10-year rate of 59.9%, according to data published in Rheumatology.
Lung abnormalities persist in some patients 2 years after COVID-19 infection
Thirty-nine percent of patients who suffered a COVID-19 infection had interstitial lung abnormalities 2 years following the illness, according to study results published in Radiology.
Q&A: Treating pulmonary hypertension-ILD with high-dose inhaled treprostinil
Inhaled treprostinil is used to treat pulmonary hypertension with interstitial lung disease, and a study recently found that higher doses led to better clinical outcomes than a lower dose or placebo.
Suspected ILD among patients with interstitial lung abnormalities linked to high mortality
About half of patients with interstitial lung abnormalities had suspected interstitial lung disease, with these patients having greater symptoms and more unfavorable clinical outcomes, according to study results.